Justin A. Caravella

Intarcia Therapeutics (United States) — United States

Medicine · Health Sciences

17h-index1.6kcitations33works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(6), Monoclonal and Polyclonal Antibodies Research(6), Cancer, Hypoxia, and Metabolism(4), Ubiquitin and proteasome pathways(4), Protein purification and stability(4)

Publications33 total

Structurally Enabling ADMET Anti-Targets via Induced Fit Docking and Free Energy Perturbation
2026Open Access
Structurally Enabling ADMET Anti-Targets via Induced Fit Docking and Free Energy Perturbation
2026Open Access
Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement
2026Open Access
Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors
Cancer Research·2025· 3 cited
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumors
European Journal of Cancer·2024
Discovery and characterization of novel inhibitors of CTP synthase 1 (CTPS1) for the treatment of autoimmune and inflammatory disease
The Journal of Immunology·2023· 2 citedOpen Access
Correction: The deubiquitylase USP9X controls ribosomal stalling
The Journal of Cell Biology·2021· 6 citedOpen Access
The deubiquitylase USP9X controls ribosomal stalling
The Journal of Cell Biology·2020· 43 citedOpen Access
The deubiquitylase USP9X controls ribosomal stalling
2020· 4 citedOpen Access
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
Journal of Medicinal Chemistry·2020· 133 citedOpen Access
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors
Journal of Medicinal Chemistry·2019· 46 citedOpen Access
Molecular basis of USP7 inhibition by selective small-molecule inhibitors
Nature·2017· 448 cited
Discovery of biaryls as RORγ inverse agonists by using structure-based design
Bioorganic & Medicinal Chemistry Letters·2016· 19 citedOpen Access
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists
Bioorganic & Medicinal Chemistry Letters·2014· 17 citedOpen Access
Highly covarying residues have a functional role in antibody constant domains
Proteins Structure Function and Bioinformatics·2013· 6 cited
Metric to Distinguish Closely Related Domain Families Using Sequence Information
Journal of Molecular Biology·2012
Dynamic Structural Changes Are Observed upon Collagen and Metal Ion Binding to the Integrin α1 I Domain
Journal of Biological Chemistry·2012· 16 citedOpen Access
Therapeutic Proteins
Methods in molecular biology·2012· 19 citedOpen Access
Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene
Bioorganic & Medicinal Chemistry Letters·2011· 34 citedOpen Access
Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
Bioorganic & Medicinal Chemistry Letters·2010· 60 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Angela V. Toms(8), Derek J. Parks(8), Christopher J. Dinsmore(6), Katrina L. Creech(6), David N. Deaton(6), Shawn P. Williams(6), Samantha Carreiro(6), Kevin P. Madauss(5), Harry B. Marr(5), Aaron B. Miller(5), Dan Todd(5), G. Bruce Wisely(5), Marie Katz(5), Peter J. Tummino(5), Stephanos Ioannidis(4), Adán Pinto-Fernández(4), Claire Heride(4), Bruce Follows(4), Crystal McKinnon(4), Tim Hammonds(4)